Investor Presentation Q1 2023
36
Investor presentation
First three months of 2023
B-cell function
Diabetes is a chronic disease requiring treatment
intensification over time
Diet and exercise
OAD
GLP-1
Insulin
Distribution of estimated prescriptions¹ and value
across treatment classes
51%
3%
12%
21%
3%
34%
13%
12%
0.4%
4%
28%
19%
Time
Estimated Prescriptions
■GLP-1 Inj.
DPP-4i
Value
Oral GLP-1
Trad. OAD
Insulin
SGLT-2i
1The estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions.
Note: Other OADs cover: metformin, sulfonylurea, thiazolidinediones. OAD: Oral anti-diabetic
Source: MIDAS; patient and value figures based on IQVIA MAT, Feb 2023
Novo NordiskⓇView entire presentation